



Dilantha Perera (Autor)

**A toolkit to study nuclear transport pathways:  
nanobody-mediated inhibition of importin  $\beta$ -related  
nuclear transport receptors (NTRs)**

Dilantha Perera

**A toolkit to study  
nuclear transport pathways:  
nanobody-mediated inhibition  
of importin  $\beta$ -related nuclear  
transport receptors (NTRs)**

 Cuvillier Verlag Göttingen  
Internationaler wissenschaftlicher Fachverlag

<https://cuvillier.de/de/shop/publications/8870>

Copyright:

Cuvillier Verlag, Inhaberin Annette Jentsch-Cuvillier, Nonnenstieg 8, 37075 Göttingen,  
Germany

Telefon: +49 (0)551 54724-0, E-Mail: [info@cuvillier.de](mailto:info@cuvillier.de), Website: <https://cuvillier.de>

# Table of Contents

<b>Thesis Committee and Examination Board Members</b>	<b>i</b>
<b>Epigraph</b>	<b>ii</b>
<b>List of Figures</b>	<b>vi</b>
<b>List of Tables</b>	<b>viii</b>
<b>Summary</b>	<b>1</b>
<b>1 Introduction</b>	<b>2</b>
<b>1.1 Compartmentalization of eukaryotic cells</b>	<b>2</b>
<b>1.2 Nuclear pore complex</b>	<b>2</b>
1.2.1 Architecture of the NPC	3
<b>1.3 Permeability barrier of the NPC</b>	<b>3</b>
1.3.1 FG repeat domains and FG-Nups	4
1.3.2 Models of NPC Transport selectivity	5
<b>1.4 Nuclear transport receptors</b>	<b>7</b>
1.4.1 Characteristics of Importin $\beta$ -like NTRs	7
1.4.2 RanGTP gradient and NTR transport directionality	8
1.4.3 RanGTP interaction with Importin $\beta$ -like NTRs	10
1.4.4 Nuclear transport pathways	11
1.4.5 NTR cargo recognition	13
<b>1.5 Overview of selected NTRs</b>	<b>14</b>
1.5.1 Transportin 1	14
1.5.2 Exportin 4 and Exportin 7	16
1.5.3 CAS	18
<b>1.6 Tools to investigate NTR mediated transport pathways</b>	<b>20</b>
1.6.1 Genetic perturbations	20
1.6.2 Targeted protein degradation	21
1.6.3 NTR inhibition using small molecules	21
1.6.4 Nanobodies to investigate NTR pathways	22
<b>1.7 Nanobodies</b>	<b>22</b>
1.7.1 Nanobody library generation	23
1.7.2 Nanobody selection: phage display	24
<b>1.8 Aim of this study</b>	<b>26</b>
<b>2 Results</b>	<b>27</b>
<b>2.1 Biochemical characterization of anti-NTR nanobodies</b>	<b>27</b>
2.1.1 Nanobodies selected against TRN1	28
2.1.2 Nanobodies selected against Xpo7	31
2.1.3 Nanobodies selected against Xpo4	34

2.1.4 Nanobodies selected against CAS	37
<b>2.2 <i>In vivo</i> validation of Nb-mediated NTR pathway inhibition</b>	<b>39</b>
2.2.1 Inhibition of the TRN1 pathway in HeLa cells	39
2.2.2 Inhibition of the CAS pathway in HeLa cells	40
<b>2.3 Inhibition of NTR-facilitated transport through NPCs in permeabilized cells</b>	<b>41</b>
2.3.1 Nb-mediated inhibition of TRN1	43
2.3.2 Nb-mediated inhibition of Xpo7	46
2.3.3 Nb-mediated inhibition of Xpo4	48
2.3.4 Nb-mediated inhibition of CAS	51
<b>2.4 Tag-Nbs to interrupt NTR-facilitated transport through NPCs in permeabilized cells</b>	<b>55</b>
2.4.1 Inhibition of TRN1	55
2.4.2 Inhibition of Xpo7	58
2.4.3 Inhibition of Xpo4	61
2.4.4 Inhibition of CAS	64
<b>2.5 Impeding NTR-facilitated transport into reconstituted FG hydrogels</b>	<b>67</b>
2.5.1 Impeding TRN1-facilitated partitioning into FG particles	68
2.5.2 Impeding Xpo7-facilitated partitioning into FG particles	70
2.5.3 Impeding Xpo4-facilitated partitioning into FG particles	71
2.5.4 Impeding CAS-facilitated partitioning into FG particles	72
2.5.5 Orthogonal tag-Nbs to impede NTR-facilitated partitioning into FG particles	73
<b>3 Discussion</b>	<b>76</b>
<b>3.1 Functional classification of the selected anti-NTR Nbs</b>	<b>76</b>
3.1.1 Semi-inhibitory nanobodies	76
3.1.2 Mildly inhibitory Nbs	78
3.1.3 NTR blockers: red lights on the NTR pathway	79
<b>3.2 Tag-Nbs: the good, the bad, and the redundant</b>	<b>80</b>
3.2.1 The benefits of tag-Nbs	80
3.2.2 Disadvantages and redundancies of tag-Nbs	82
3.2.3 Orthogonal tag-Nbs	84
<b>3.3 Future Outlook</b>	<b>85</b>
3.3.1 Expanding and improving the toolkit	85
3.3.2 Studying the mechanics of Nb-NTR and FG-NTR interactions	86
3.3.3 Unravelling the NTR transport network	86
<b>4 Materials and Methods</b>	<b>88</b>
<b>4.1 Chemicals, proteins, and reagents</b>	<b>88</b>
<b>4.2 Molecular cloning</b>	<b>88</b>
4.2.1 Design and validation	88
4.2.2 Polymerase chain reaction (PCR)	88
4.2.3 Agarose gel electrophoresis	89
4.2.4 Gibson assembly	90

4.2.5 Transformation of bacteria	90
4.2.6 Plasmid DNA preparation	90
<b>4.3 Protein purification</b>	<b>91</b>
4.3.1 Recombinant protein expression	91
4.3.1 Recombinant expression of Nb constructs	92
4.3.2 Immobilized metal ion chromatography	93
4.3.3 Size exclusion chromatography	94
4.3.4 SDS-PAGE	95
4.3.5 Protein labeling using maleimide chemistry	95
<b>4.4 Binding assays</b>	<b>96</b>
4.4.1 Pulldown assays	96
4.4.2 BioLayer Interferometry (BLI)	97
<b>4.5 <i>In vivo</i> experiments</b>	<b>98</b>
4.5.1 Cell culture	98
4.5.2 Transient transfection of HeLa cells	98
4.5.3 Confocal fluorescence microscopy	99
<b>4.6 Permeabilized cell assays</b>	<b>99</b>
4.6.1 Permeabilization of HeLa cells	99
4.6.2 Confocal fluorescence microscopy	100
4.6.3 Data analysis	101
<b>4.7 Experiment using FG phase hydrogels</b>	<b>101</b>
4.7.1 Expression and purification of Nup116 FG domains	101
4.7.2 FG particle assay	103
4.7.3 Confocal fluorescence microscopy	103
4.7.4 Data analysis	104
<b>References</b>	<b>105</b>
<b>Acknowledgements</b>	<b>120</b>
<b>Curriculum vitae</b>	<b>121</b>